Brief: Bio-Path Holdings Provides Update From Phase 1/1B Clinical Trial Of Bp1002 For Treatment Of Refractory/Relapsed Acute Myeloid Leukemia
12/02/2025 22:44
Bio Path Holdings Inc BPTH.O :
* BIO-PATH HOLDINGS PROVIDES UPDATE FROM PHASE 1/1B CLINICAL
TRIAL
OF BP1002 FOR TREATMENT OF REFRACTORY/RELAPSED ACUTE MYELOID
LEUKEMIA
Source text: ID:nGNXbZ7Jcj
Further company coverage: BPTH.O
Recent news on Bio Path Holdings
See all newsBrief: Bio-Path Holdings Seeks Financing For Turnaround & Strategic Actions
Brief: Bio-Path Holdings Reports Full Year 2024 Financial Results
Brief: Bio-Path Holdings Announces Pre-Clinical Results Signaling Increased Potential for BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients
Brief: Bio-Path Provides Key Clinical Updates
Brief: Bio-Path Holdings Provides Update From Phase 1/1B Clinical Trial Of Bp1002 For Treatment Of Refractory/Relapsed Acute Myeloid Leukemia